Bridgette M Collins-Burow

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7200056/publications.pdf

Version: 2024-02-01

21	297	933447 10	888059 17
papers	citations	h-index	g-index

23	23	23	494
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Multifunctional profiling of triple-negative breast cancer patient-derived tumoroids for disease modeling. SLAS Discovery, 2022, 27, 191-200.	2.7	7
2	436 Examining the Role of Obesity and Leptin Signaling in Triple Negative Breast Cancer. Journal of Clinical and Translational Science, 2022, 6, 86-86.	0.6	0
3	Breast Cancer-Stromal Interactions: Adipose-Derived Stromal/Stem Cell Age and Cancer Subtype Mediated Remodeling. Stem Cells and Development, 2022, 31, 604-620.	2.1	3
4	Application of a small molecule inhibitor screen approach to identify CXCR4 downstream signaling pathways that promote a mesenchymal and fulvestrantâ€'resistant phenotype in breast cancer cells. Oncology Letters, 2021, 21, 380.	1.8	1
5	Dual inhibition of MEK1/2 and MEK5 suppresses the EMT/migration axis in tripleâ€'negative breast cancer through FRAâ€1 regulation. Journal of Cellular Biochemistry, 2021, 122, 835-850.	2.6	5
6	NEK5 activity regulates the mesenchymal and migratory phenotype in breast cancer cells. Breast Cancer Research and Treatment, 2021, 189, 49-61.	2.5	10
7	Targeting Never-In-Mitosis-A Related Kinase 5 in Cancer: A Review. Current Medicinal Chemistry, 2021, 28, 6096-6109.	2.4	5
8	A Role for Adipocytes and Adipose Stem Cells in the Breast Tumor Microenvironment and Regenerative Medicine. Frontiers in Physiology, 2021, 12, 751239.	2.8	15
9	Evaluation of deacetylase inhibition in metaplastic breast carcinoma using multiple derivations of preclinical models of a new patient-derived tumor. PLoS ONE, 2020, 15, e0226464.	2.5	13
10	ERK5 Is Required for Tumor Growth and Maintenance Through Regulation of the Extracellular Matrix in Triple Negative Breast Cancer. Frontiers in Oncology, 2020, 10, 1164.	2.8	13
11	A novel screening approach comparing kinase activity of small molecule inhibitors with similar molecular structures and distinct biologic effects in triple-negative breast cancer to identify targetable signaling pathways. Anti-Cancer Drugs, 2020, 31, 759-775.	1.4	0
12	Patient-Derived Xenografts as an Innovative Surrogate Tumor Model for the Investigation of Health Disparities in Triple Negative Breast Cancer. Women S Health Reports, 2020, 1, 383-392.	0.8	4
13	Pharmacological, Mechanistic, and Pharmacokinetic Assessment of Novel Melatonin-Tamoxifen Drug Conjugates as Breast Cancer Drugs. Molecular Pharmacology, 2019, 96, 272-296.	2.3	30
14	Obesity-Altered Adipose Stem Cells Promote ER+ Breast Cancer Metastasis through Estrogen Independent Pathways. International Journal of Molecular Sciences, 2019, 20, 1419.	4.1	29
15	Drug resistance profiling of a new triple negative breast cancer patient-derived xenograft model. BMC Cancer, 2019, 19, 205.	2.6	19
16	A novel patient-derived xenograft model for claudin-low triple-negative breast cancer. Breast Cancer Research and Treatment, 2018, 169, 381-390.	2.5	19
17	Panobinostat suppresses the mesenchymal phenotype in a novel claudin-low triple negative patient-derived breast cancer model. Oncoscience, 2018, 5, 99-108.	2.2	15
18	Dual Src Kinase/Pretubulin Inhibitor KX-01, Sensitizes ERÎ±-negative Breast Cancers to Tamoxifen through ERÎ± Reexpression. Molecular Cancer Research, 2017, 15, 1491-1502.	3.4	12

#	Article	IF	Citations
19	Argonaute 2 Expression Correlates with a Luminal B Breast Cancer Subtype and Induces Estrogen Receptor Alpha Isoform Variation. Non-coding RNA, 2016, 2, 8.	2.6	11
20	Suppression of triple-negative breast cancer metastasis by pan-DAC inhibitor panobinostat via inhibition of ZEB family of EMT master regulators. Breast Cancer Research and Treatment, 2014, 145, 593-604.	2.5	85
21	Liver Kinase B1 Regulates Remodeling of the Tumor Microenvironment in Triple-Negative Breast Cancer. Frontiers in Molecular Biosciences, 0, 9, .	3.5	1